Comments on: Trends Update — IP Constituencies: India’s Glenmark Pharmaceuticals Sets an Example for Canadian Innovation

By: IP Constituencies: Indian Industry Lobbies to Keep IP Out of Free Trade Agreement with EU | RIC Centre

Mon, 04 Jul 2011 14:55:20 +0000

[...] IP provisions out of the free trade agreement being negotiated between India and the EU. But, with Glenmark and Jubilant on the rise, and with even Biocon carrying the R&D water in its deal with Pfizer, [...]

By: IP Constituencies: Indian Industry Lobbies to Keep IP Out of Free Trade Agreement with EU | RIC Centre Blog

Thu, 16 Dec 2010 11:48:22 +0000

By: IP Constituencies: Indian Industry Lobbies to Keep IP Out of Free Trade Agreement with EU « The RIC Blog

Thu, 16 Dec 2010 11:41:29 +0000

By: Biotech Trends Update — IP Constituencies: Indian Industry Lobbies to Keep IP Out of Free Trade Agreement with EU « The Cross-Border Biotech Blog

Tue, 07 Dec 2010 16:32:40 +0000

By: Biotech Trends Update — IP Constituencies: India’s Courts Nix Drug Patents while India Courts Innovation « The Cross-Border Biotech Blog

Tue, 02 Mar 2010 12:03:25 +0000

[...] The trend toward innovation in India is undeniable — as the WSJ’s Venture Capital Blog noted recently, India even has its own version of Y Combinator, an incubator/early-stage fund. India also has many notable successes in pharma and biotech innovation, including Jubilant and Glenmark. [...]

By: Biotech Trends Update — IP Constituencies: Innovators and Generics Continue to Blur Pharma Lines « The Cross-Border Biotech Blog

Mon, 11 Jan 2010 16:42:21 +0000

[...] those to increasing innovation in India and China and in collaborations with companies there, and the whole global industry is starting to [...]